Compare Invesco DB Oil Fund (DBO) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Oil Fund vs Illumina, Inc. — how do they compare? Invesco DB Oil Fund trades at $19.88, while Illumina, Inc. trades at $192.32 (market cap $28.93B). The key difference: Illumina, Inc. is trading nearer its 52-week high, Invesco DB Oil Fund nearer its low. Which is the better fit depends on your goals.
| DBO | ILMN | |
|---|---|---|
Sector | Commodities - Energy | Health |
52-Week High | $23.80 | $194.33 |
52-Week Low | $11.98 | $91.00 |
Market Cap | — | $28.93B |
Enterprise Value | — | $30.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBO is trading at $19.59, up 8.47% with strong bullish momentum driven by escalating Middle East tensions that are boosting oil prices. Technical indicators show a bullish trend with support at $19 and resistance at $20, though RSI suggests potential overbought conditions. The stock benefits from geopolitical events that typically drive energy sector performance.
The outlook remains positive as oil price strength translates to potential revenue growth for US energy companies. Key risks include geopolitical volatility and potential supply disruptions. Analyst sentiment appears constructive given the favorable oil market dynamics, though fundamental metrics require verification from recent SEC filings.
Illumina (ILMN) trades at $190.05, showing strong momentum with a 43.7% gain year-to-date and recent earnings beats. The stock is technically bullish, trading near resistance at $191 with solid fundamentals including 19.42% net margins and robust cash flow. Recent leadership appointments and product launches like StrataMap Spatial Solution highlight ongoing innovation in genomics sequencing.
Outlook remains positive driven by sequencing demand and margin expansion, but risks include competitive pressure from Roche's new sequencer and China market weakness. Analyst consensus is bullish with 51% buy ratings, though the current price exceeds the $174.44 target, suggesting near-term valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Invesco DB Oil Fund
DBO provides exposure to WTI crude oil prices through futures contracts. It is designed for investors seeking a way to invest in the performance of the fossil fuel market without purchasing physical oil barrels.
Read more on DBO →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
